NEW YORK (GenomeWeb) – Definiens and Indivumed announced today that they have formed a strategic partnership combining their respective technologies and services in image analysis and tissue-based cancer biomarker research and development.
Under the terms of the arrangement, the companies will offer their customers Definiens' Cognition Network data-mining and Tissue Phenomics image-analysis technologies along with Indivumed's cancer database, biobank, and analytical laboratory services.
Additional terms of the deal were not disclosed.
"In the quest to use tissue biomarkers to create diagnostic tests for cancer patients, there is no question that the quality of tissue combined with advanced image analysis and tissue mining is extremely important," Definiens Chief Medical Officer Ralf Huss said in a statement. "This partnership allows researchers and clinicians to benefit from the expertise of both our companies and advance personalized medicine for the treatment of patients."